패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

argenx SE 48 애널리스트 중 28 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Joel Beatty	Baird
Charles Pitman-King	Barclays
Richard Parkes	BNP Paribas Exane

argenx 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Recent updates

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

argenx SE Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Argenx Se Advances Clinical Development of Efgartigimod Sc in Idiopathic Inflammatory Myopathies

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

argenx: Myositis Data Could Add Billions In Value

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Argenx: Strong Setup For Outperformance In 2025

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx: Innovation Over Losses In Autoimmune Arena

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx: A Very Good Start For Vyvgart

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

argenx: R&D Day Goes Unnoticed

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in the Lancet Neurology

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

argenx SE Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

argenx Issues Statement Concerning Efgartigimod

Argenx raises ~$1B in global offering

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

argenx to raise $750M in proposed global offering

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx on target to file efgartigimod applications in Japan and Europe

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Argenx inks $98M deal to secure accelared review status for efgartigimod

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx (ARGX) Investor Presentation - Slideshow

argenx Announces Partnership with Chugai and the Clayton Foundation

재무 상태 분석